Ovarian cancer is hard to detect because it produces only vague symptoms, grows in a hidden location deep in the pelvis, and lacks a reliable screening test. Four out of five patients are diagnosed with advanced disease, largely because every tool available today has significant blind spots. The gap between early and late detection is stark: the five-year survival rate for localized ovarian cancer is 92%, but it drops to 32% once the cancer has spread to distant sites.
The Symptoms Mimic Everyday Problems
The most common signs of ovarian cancer are bloating, abdominal pain, diarrhea, feeling full quickly, and fatigue. Some oncologists use the acronym BEACH to remember them: Bloating, Early satiety, Abdominal pain, Changes to bowel or bladder habits, and Heightened fatigue. Every one of these symptoms also shows up with indigestion, a stomach virus, irritable bowel syndrome, or a normal menstrual cycle. That overlap means both patients and doctors frequently attribute the symptoms to something routine, especially because the discomfort tends to build gradually rather than arriving all at once.
There is no single “red flag” symptom that points clearly to ovarian cancer the way a lump does for breast cancer. Instead, the pattern that matters is persistence. When bloating or pelvic pressure happens nearly every day for two or three weeks and has no obvious explanation, that consistency is what distinguishes it from a passing GI issue. But recognizing that pattern requires a level of body awareness that’s easy to miss in the moment.
The Ovaries Are Difficult to Examine
Each ovary is only about 2 to 4 centimeters across, roughly the size of an almond. They sit on the posterior wall of the pelvis, tucked behind the uterus and surrounded by other organs. That depth makes them nearly impossible to feel during a standard pelvic exam, particularly in the early stages of a tumor when the ovary hasn’t changed much in size. Unlike cervical cancer, which develops on a surface that can be swabbed and sampled, ovarian cancer grows in a space that isn’t easily accessed without imaging or surgery.
No Screening Test Works Well Enough
Two tools have been studied extensively for ovarian cancer screening: a blood test that measures a protein called CA-125, and transvaginal ultrasound. Neither is recommended for routine use.
CA-125 levels are elevated in only about 50% of early-stage ovarian cancers. That means roughly half of women with early disease would get a normal result and be falsely reassured. The test also has a specificity of only 73 to 77%, because CA-125 rises in plenty of non-cancerous situations. About 1% of healthy women and 5% of women with conditions like endometriosis show elevated levels. In advanced disease, CA-125 is abnormal in 92% of cases, but by that point the cancer has already spread.
Transvaginal ultrasound has its own limitations. Early malignant tumors and benign cysts can look alike on imaging, and some high-grade serous ovarian cancers produce minimal or no visible abnormalities on ultrasound at all. Tumors smaller than 10 millimeters are particularly hard to spot, and research shows that some of those small tumors have already metastasized before reaching a size ultrasound can detect. Adding to the challenge, some ovarian cancers actually originate in the fimbriae of the fallopian tubes, a structure that ultrasound cannot easily visualize.
Because of these problems, the U.S. Preventive Services Task Force recommends against routine ovarian cancer screening for average-risk women. The task force concluded with moderate certainty that the harms of screening, including unnecessary surgeries prompted by false positives, outweigh the benefits.
The Cancer Spreads Before It Grows
Most cancers spread through the bloodstream or lymphatic system, but ovarian cancer has an additional route that makes it especially dangerous. Cancer cells can shed directly off the ovary’s surface and float through the fluid that naturally fills the abdominal cavity. This process, called transcoelomic dissemination, allows the cancer to reach the lining of the abdomen, the omentum (a fatty tissue that drapes over the intestines), and other nearby organs without ever entering a blood vessel.
The fluid in the abdominal cavity essentially acts as a transport medium, carrying loose cancer cells to new surfaces where they can implant and grow. This means ovarian cancer can spread widely while the primary tumor is still small, sometimes too small to detect on imaging. It’s one of the main reasons the most common and aggressive subtype, high-grade serous carcinoma, is diagnosed at stage III in 51% of cases and stage IV in 29%.
What This Means for Different Risk Levels
For women at average risk, there is currently no proven way to screen for ovarian cancer. The best available strategy is paying close attention to persistent, unexplained symptoms, particularly the BEACH symptoms occurring most days over several weeks, and raising them with a doctor promptly rather than assuming they’ll pass.
For women at high risk, particularly those who carry BRCA1 or BRCA2 gene mutations, the CDC outlines a different set of options. These include screening with transvaginal ultrasound and CA-125 blood tests, though the effectiveness of this approach is less certain than other measures. The most effective prevention for high-risk women is surgical removal of the ovaries and fallopian tubes. Medications that lower cancer risk are also an option. These decisions are highly individual and depend on factors like age, family planning, and the specific mutation involved.
Why Early Detection Matters So Much
The survival gap between early and late diagnosis is larger in ovarian cancer than in many other cancers. Women diagnosed when the cancer is still localized to the ovary have a 92% five-year survival rate. Once the cancer has spread regionally, that drops to 71%. At the distant stage, where most patients are diagnosed, survival falls to 32%. Not all subtypes behave the same way: endometrioid, mucinous, and clear cell carcinomas are diagnosed at stage I in 58 to 64% of cases, and these types carry a substantially better prognosis. High-grade serous carcinoma, which accounts for the majority of ovarian cancer deaths, is the subtype most likely to be caught late.
Researchers are exploring blood-based tests that analyze fragments of tumor DNA circulating in the bloodstream. Newer laboratory techniques have pushed detection rates for this circulating DNA up to around 80% in some studies, but sensitivity remains poor for early-stage disease. For now, these tests are more useful for tracking treatment response in patients already diagnosed than for catching the cancer in the first place.